Business

CiplaQCIL Notes A Marked Growth In Revenue During Annual Results Discussion

CiplaQCIL Notes A Marked Growth In Revenue During Annual Results Discussion

Cipla Quality Chemical Industries Limited (CiplaQCIL) on Wednesday hosted their first ever annual results discussion at Golden Tulip Hotel.

In attendance were several company officials, stock brokers from Equity Bank and representatives from different media companies.

Cipla QCIL is a company based in Uganda that deals in the manufacture of drugs (ACTS, antiretroviral and hepatitis medicines). The company strongly believes in creating life saving medicine.

Following the start of a new financial year, the company decided to lay down the facts behind the figures.

Mr. Frederick kakooza, the Chief Finance Officer kick-started the event by noting that despite the setbacks, the company has still managed to deliver very good performance as the company’s revenue grew by 3% excluding the revenue from COVID sales (24 Billion UGX). Net profit margin has improved by 12% minus exceptional. The company’s compounded annual growth rate is 8%.

He continued to breakdown the revenues collected in therapeutic areas. In the year under analysis, UGX 201 billion was collected from ARVS, UGX 57 billion from antimalarials and UGX 9 billion from private business.

Management profit (EBITDA) where management is appraised summed up to UGX 48 billion compared UGX 1billion in the previous year. This is inclusive of profits made from Zambia. The company’s overall net profit was UGX 24 billion compared to a loss of UGX 11 billion in the previous year. CIPLA-QCIL pays a monthly bill of UGX 6.3 million.

Mr. Fred Kakooza noted that the company’s ratios too had greatly improved.

During Mr. Ajay Kumar Apal’s address, the company CEO commended the staff for a good performance and also for observing safety precautions as the company hasn’t registered any deaths as a result of factory related accidents.

He further stated that the company’s derives inspiration from its aspirations and the impact it wants to create on the continent. He further emphasized that Cipla QCIL cares for human life in many aspects such as health and employment.

He added “we became the first company who has produced COVID treatment outside first world countries and India.” The said product is waiting full approval from National Drug Authority ((NDA).

Mr. Ajay also confirmed that the company intends to produce a drug used in the treatment of sickle cell anemia. He also mentioned that the company employs about 500 employees directly and is also the biggest driver for blood donation campaigns.

The four main areas targeted by CIPLA QCIL’s business model include; cost leadership, growth ad sustainability, balance profitability & investment and business development.

Paula Ashaba
Author
Paula Ashaba